From: A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
 | Placebo group | Tropisetron group | P value |
---|---|---|---|
Sex (M/F) | 10/10 | 9/11 | NSa |
Age | 35.15 ± 8.54 | 34.96 ± 6.82 | NSb |
Subtype | Disorganised 1 | Disorganised 0 | NSa |
 | Catatonia 1 | Catatonia 0 |  |
 | Paranoid 13 | Paranoid 11 |  |
 | Undifferentiated 2 | Undifferentiated 3 |  |
 | Residual 3 | Residual 6 |  |
Duration of illness | 9.79 ± 6.43 | 12 ± 8.67 | NSb |
Dose of risperidone | 3.8 ± 1.58 | 4.03 ± 1.59 | NSb |
No. smoking | 5 (25%) | 6 (30%) | NSa |
Full IQ | 87.00 ± 16.80 | 87.68 ± 18.86 | NSb |
PANSS score | Positive: 11.8 ± 3.12 | Positive: 11.85 ± 3.22 | NSb |
 | Negative: 18.45 ± 6.66 | Negative: 18.95 ± 5.23 |  |
 | General: 34.3 ± 7.53 | General: 33.75 ± 8.69 |  |
 | Total: 64.55 ± 15.17 | Total: 64.55 ± 15.65 |  |
QLS total score | 77.05 ± 15.8 | 72.2 ± 13.95 | NSb |
Rate of completion | 17 (85%) | 16 (80%) | NSa |
Reason for dropout | Physical illness: 1 | Non-adherence: 2 | Â |
 | Worsening of illness: 1 | Unknown: 1 |  |
 | Adverse effects: 1 (extrapyramidal signs) | Adverse effect: 1 (chest pain) |  |